The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck

(2019) Rachel J. Carter et al.   Cell Death & Disease

Intrinsic Instability of BOK Enables Membrane Permeabilization in Apoptosis

(2018) Janet H. Zheng et al.   Cell Reports

A review of soft-tissue sarcomas: translation of biological advances into treatment measures

(2018) Ngoc T Hoang et al.   Cancer Management and Research

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Metastability, an emerging concept governing BOK-mediated apoptosis initiation

(2018) Tudor Moldoveanu et al.   Oncotarget

Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax

(2018) Daniel Stehle et al.   Scientific Reports

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

(2017) William D Tap et al.   LANCET ONCOLOGY

Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia

(2017) J Deng et al.   LEUKEMIA

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

(2017) Akane Inoue-Yamauchi et al.   Nature Communications

Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells

(2017) Effrosini G. Panayotopoulou et al.   Oncotarget

Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die

(2017) Benjamin Onyeagucha et al.   Oncotarget

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

(2017) Gino K. In et al.   Therapeutic Advances in Medical Oncology

ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer

(2017) Eun Young Kim et al.   NEOPLASIA

A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.

(2017) S. Attia et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

(2016) N. Shukla et al.   CANCER RESEARCH

BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation

(2016) Fabien Llambi et al.   CELL

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

(2016) AW Roberts et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak

(2016) Stephanie Einsele-Scholz et al.   JOURNAL OF CELL SCIENCE

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

(2015) Milan Bruncko et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

(2015) S M Matulis et al.   LEUKEMIA

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets

(2015) Sujana Movva et al.   Oncotarget

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

(2014) Lenka Kubiczkova et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Targeted polytherapy in small cell sarcoma and its association with doxorubicin

(2014) S.N. Dumont et al.   Molecular Oncology

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4

(2013) M. Gutekunst et al.   CANCER RESEARCH

Intracellular localization of the BCL-2 family member BOK and functional implications

(2013) N Echeverry et al.   CELL DEATH AND DIFFERENTIATION

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1

(2012) A Craxton et al.   CELL DEATH AND DIFFERENTIATION

Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol

(2011) Frank Edlich et al.   CELL

Bcl-2 family interactome analysis using bacterial surface display

(2011) Siyan Zhang et al.   Integrative Biology

Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX

(2010) Bonsu Ku et al.   CELL RESEARCH

Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells

(2010) M. Baou et al.   HAEMATOLOGICA

The Anti-apoptotic Protein BCL2L1/Bcl-xL Is Neutralized by Pro-apoptotic PMAIP1/Noxa in Neuroblastoma, Thereby Determining Bortezomib Sensitivity Independent of Prosurvival MCL1 Expression

(2010) Judith Hagenbuchner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Determinants of BH3 Binding Specificity for Mcl-1 versus Bcl-xL

(2010) Sanjib Dutta et al.   JOURNAL OF MOLECULAR BIOLOGY

Targeting mitochondria for cancer therapy

(2010) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY

Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax

(2008) Jonathan F. Lovell et al.   CELL

Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax

(2008) J. I. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA